ZymoGenetics builds cash reserves as it advances Thrombin

Seattle-based ZymoGenetics has added $125 million to its cash reserves, bringing total cash on hand to about $400 million. Company execs say that much of the money will go to a late-stage trial of Thrombin, an experimental drug to control bleeding during surgery. The funds will also help bankroll the creation of a 50-man sales force that will be assembled to market Thrombin once it receives FDA approval.

- read this article in the Seattle Post-Intelligencer for more

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.